Jubilant Life receives USFDA nod for hypertension tablets
As on 30 June, 2016, Jubilant Life Sciences had a total of 770 filings for Oral Solids of which 578 have been approved in various regions globally
New Delhi: Jubilant Life Sciences Wednesday said it has received approval from the US health regulator for Telmisartan Tablets, used for the treatment of hypertension, in the American market.
In a BSE filing, the company said "it has received Abbreviated New Drug Application (ANDA) final approval for Telmisartan Tablets, USP 20,40 and 80mg, the generic version of Micardis Tablets of Boehringer Ingelheim Pharmaceuticals Inc".
As on 30 June, 2016, Jubilant Life Sciences had a total of 770 filings for Oral Solids of which 578 have been approved in various regions globally.
"This includes 70 ANDAs filed in the US, of which 44 have been approved and 104 filings in Europe," it said.
Sectors like FMCG, PSU Bank, auto, and metal indices witnessed a hike of 1-3 percent while the IT index saw a decrease of nearly one percent
BSE Midcap saw a rise of 1.56 percent to end up 408.47 points higher at 26,556.43, while BSE Smallcap rose by 0.59 percent to end up 173.15 points higher at 29,755.41.
Maruti Suzuki, Power Grid, ITC, NTPC and SBI have been the top Sensex gainers